Mycoplasma genitalium Testing: When CDC Recommends It—and When It Does Not
Why M. genitalium is not a routine screening test for everyone, and when persistent or recurrent symptoms change the equation.
The decision in one minute
The key is to separate what this can tell you from what it cannot: CDC does not recommend screening asymptomatic people for M. genitalium. Testing is more relevant in recurrent nongonococcal urethritis, recurrent cervicitis, and selected pelvic inflammatory disease situations.
Why M. genitalium is not a routine screening test for everyone, and when persistent or recurrent symptoms change the equation. This page stays focused on test selection, so you can use the information to make one concrete next decision instead of collecting more disconnected facts.
What changes the answer
One concrete point: CDC does not recommend routine screening for asymptomatic M. genitalium infection.
A detail people often miss: Men with recurrent nongonococcal urethritis should be tested with an FDA-cleared NAAT; women with recurrent cervicitis should be tested, and testing may be considered with PID.
| Check | Why it belongs in your decision |
|---|---|
| Point 1 | CDC does not recommend routine screening for asymptomatic M. genitalium infection. |
| Point 2 | Men with recurrent nongonococcal urethritis should be tested with an FDA-cleared NAAT; women with recurrent cervicitis should be tested, and testing may be considered with PID. |
| Point 3 | Resistance is a major reason M. genitalium management is different from routine chlamydia testing. |
| Point 4 | Extragenital screening for M. genitalium is not recommended by CDC. |
| Point 5 | Persistent symptoms after empiric treatment are a reason for clinician-guided testing rather than repeatedly ordering broad panels. |
The details that are easy to miss
This matters because resistance is a major reason M. genitalium management is different from routine chlamydia testing.
One concrete point: Extragenital screening for M. genitalium is not recommended by CDC.
How to use the information without overreading it
The evidence-guided takeaway is that Persistent symptoms after empiric treatment are a reason for clinician-guided testing rather than repeatedly ordering broad panels.
This is where people often turn a useful clue into an unsupported conclusion. The safest interpretation is the one that answers the question the test, tracker, symptom, or product was actually designed to answer—and stops there.
Three scenarios to separate
Routine screening: You feel well and are deciding what periodic testing makes sense. Use CDC/USPSTF population guidance rather than assuming every person needs the same panel on the same schedule.
Known or recent exposure: The date, infection if known, type of sex, and exposed body sites become central. If HIV exposure is plausible and occurred within 72 hours, PEP evaluation is urgent.
Symptoms: Testing may still be appropriate, but an examination can identify lesions, pelvic or testicular complications, urinary causes, vaginitis, dermatitis, or other problems a broad home panel can miss.
How to choose the test rather than the biggest panel
Read the specimen types before the organism list. A urine-only kit cannot answer a throat or rectal question.
Check the regulatory and laboratory details. FDA authorization, CLIA laboratory processing, confirmatory testing, and access to treatment are more meaningful than a giant “10-panel” badge.
Write down the last possible exposure date and any previous tests. If a negative result was obtained during a window period, ask when the exact test becomes conclusive enough for your situation.
Save-this checklist
- CDC does not recommend routine screening for asymptomatic M. genitalium infection.
- Men with recurrent nongonococcal urethritis should be tested with an FDA-cleared NAAT; women with recurrent cervicitis should be tested, and testing may be considered with PID.
- Resistance is a major reason M. genitalium management is different from routine chlamydia testing.
- Extragenital screening for M. genitalium is not recommended by CDC.
- Persistent symptoms after empiric treatment are a reason for clinician-guided testing rather than repeatedly ordering broad panels.
Quick testing-plan organizer
This is not a diagnostic calculator. It helps you organize what to tell a clinician or testing service.
Frequently asked questions
Does mycoplasma genitalium testing: when cdc recommends it—and when it does not mean I should order every available test?
No. Test selection should match the infection, exposure site, symptoms, timing, and screening guidance. A bigger commercial panel is not automatically more medically useful.
Can a negative result be too early?
Yes. Detectability varies by infection and test type. HIV has clearly published test-specific window periods; for other infections, follow the laboratory or clinician guidance and repeat testing when advised.
Should I wait if I have symptoms?
Not necessarily. Significant symptoms can justify clinical evaluation now, both for targeted STI testing and for non-STI causes that an online panel cannot diagnose.
What if the possible exposure was within 72 hours?
If HIV exposure is plausible, ask urgently about PEP. CDC says PEP must be started within 72 hours and works best when started as soon as possible.
Related reading
Primary guidance used
Guidance and product authorizations change. When timing or treatment matters, use the current linked guidance or a clinician rather than relying on a cached summary.